Occurrence and Distribution of Bone Tumors in Beagle Dogs Exposed to 90Sr

Radiation-induced bone tumors in beagle dogs exposed to ⁹⁰Sr have been evaluated in terms of their incidence, time of appearance, occurrence as multiple tumors, anatomic distribution, and the influence of sex on their development. Among dogs fed ⁹⁰Sr during skeletal development, the incidence of bone tumors was dose dependent. Tumors thus appeared in 10 of 19 dogs receiving average skeletal doses of 130 Gy, 15 of 60 receiving 97 Gy, 5 of 61 receiving 61 Gy, 2 of 65 receiving 26 Gy, and 1 of 40 receiving 1.3 Gy. No tumors appeared among 66 dogs who received 8 Gy, 78 who received 0.3 Gy, and 80 non-irradiated controls, all of which have been observed for life. Among dogs given a single intravenous injection of ⁹⁰Sr in early adulthood, tumor production was somewhat higher than among ⁹⁰Sr-fed dogs at the same radiation dose: bone tumors were present in 6 of 25 dogs who received 62 Gy and 1 of 20 dogs who received 7.5 Gy. Bone tumors appeared sooner and were more often multiple in animals receiving the higher doses. Long bones were the sites of most of the tumors appearing after the highest dose level. Bones of the head, particularly the mandible, were the predominant site of tumors in the next highest dose level group.     

Pterygium excision with or without postoperative irradiation,a double-blind study

A double-blind study (covering 40 months) of 40 eyes with a pterygium which had not previously been operated on, was carried out to study the effect of postoperative irradiation. Nineteen eyes were treated by the bare sclera operation technique only and in 13 cases (68%) a recurrence occurred within 4 months. In 18 eyes from the group of patients treated with Sr 90 irradiation on the 1st, 7th and 14th postoperative day (maximum 3×1000 rad) no recurrences were seen.Patients with a recurrent pterygium and diplopia, symblepharon, visual disturbances (growth over the pupil or severe astigmatism) or many previous operations, were treated by lamellar keratoplasty (Dake, 1980). The recurrences without these complications were treated with success by the bare sclera technique and postoperative irradiation.Complications did not occur in any of the series.     

~(89)Sr治疗骨转移癌疼痛研究

 目的　评价放射性核素89锶 (89Sr)对骨转移癌的止痛疗效和不良反应 ,并探讨其在癌性骨痛治疗中的应用范围。方法　观察 35例骨转移癌患者使用89Sr治疗后的止痛疗效、肿瘤标记物水平的变化、不良反应及血液学毒副反应。结果　89Sr止痛总有效率为 71 .4 % ,其中来源于前列腺癌和乳腺癌的骨转移癌患者有效率达到 80 .0 %。少数肿瘤标记物水平有下降。副反应主要为轻度可逆性的骨髓造血功能损害。89Sr对血生化无明显不良影响。结论　89Sr是治疗骨转移癌疼痛的一种安全有效的方法     

UV-LED用2(Sr,Ba)O-0.16B2O3-0.84P2O5:Eu2+荧光粉

以SrCO3、BaCO3、H3BO3、Eu2O3和NH4H2PO4为原料,通过高温固相法,合成了2(Sr,Ba)O-0.16B2O3-0.84P2O5:Eu2 荧光粉。通过XRD图谱、激发和发射光谱、光色参数和相对亮度的测量,研究了Ba2 对荧光粉的晶体结构以及发光性能的影响。结果表明:2(Sr,Ba)O-0.16B2O3-0.84P2O5:Eu2 荧光粉属于四方晶系,晶胞参数随Ba2 摩尔含量增加而增大。Ba2 的引入可以显著提高荧光粉的相对亮度,同时,随着Ba2 摩尔含量的增加,荧光粉的发射主峰向短波方向移动,出现蓝移,其色坐标y值逐渐减小,有利于提高白光发光二极管的流明效率和显色指数。     

89锶内照射治疗转移性骨肿瘤骨痛的临床观察

目的:分析89锶治疗转移性骨肿瘤的临床疗效及其安全性.方法:42例转移性骨肿瘤患者接受了89锶治疗.治疗后定期测定血常规、血生化等指标,随访时间3个月以上.对患者骨痛缓解情况、不良反应和血液学、肝肾功能变化进行观察和评价.结果:42例中有效35例,总有效率83.3%,起效时间2～20 d,缓解持续时间3～14个月.毒性反应主要有轻度可逆性骨髓抑制,血液学毒性小于Ⅱ级.无过敏反应及其他特殊不良反应.对肝肾功能无明显影响.结论:89锶对于转移性骨肿瘤所致的剧烈疼痛有良好的止痛效果,毒副作用小,是提高患者的生存质量的一种有效、安全的治疗方法.     

大剂量90Sr敷贴治疗瘢痕疙瘩疗效分析

目的 探讨分次大剂量法90Sr敷贴治疗瘢痕疙瘩的方法 学及临床应用价值.方法 将224例患有瘢痕疙瘩的患者随机分成两组:124例患者采用分次大剂量照射法治疗,100例患者采用常规分次小剂量照射法进行治疗,并将后者作为对照组.结果 大剂量组和常规小剂茸组在.临床治愈率、有效率和副作用发生率均有显著差异(均P＜0.05),大剂量组患者治愈率明显提高,副作用发生率也增高.结论 分次大剂量90Sr敷贴法治疗瘢痕疙瘩具有较高的临床应用价值.     

阴离子交换树脂除210Bi技术在90Sr分析中的应用

目的 为了克服现有分析标准推荐的硫化铋沉淀法除铋存在的弊端,提升分析结果质量。方法 基于201×7阴离子交换树脂设计了除铋实验流程,并通过加标样品和国际原子能机构（IAEA）国际比对样品分析予以验证。结果 采用阴离子交换树脂进行除铋。在锶、钇、铋去除实验中,锶和钇的化学回收率可分别达到（98.6±0.8）%和（98.5±0.7）%,且未发现有Bi₂S₃沉淀生成;在加标土壤分析中,所得到的分析结果与理论值的相对标准偏差为-2.97%~5.94%,优于标准除铋方法的3.96%~17.80%;采用IAEA国际比对样品进行验证,⁹⁰Sr的报出值与目标值的相对标准偏差介于3.40%~7.09%,结果均可接受。结论 阴离子交换树脂对铋能够实现很好的定量去除,同时不吸附锶和钇。另外,阴离子交换树脂的除铋溶液体系与⁹⁰Sr分析时的解吸体系相同,无需转换体系即可实现快速除铋的目的。与现行标准分析方法相比,基于阴离子交换树脂定量除铋是可行的且更优,能够满足⁹⁰Sr常规分析工作需求。     

Captopril (SQ 14,225) (d-3-mercapto-2-methylpropanoyl-l-proline): A novel orally active inhibitor of angiotensin-converting enzyme and antihypertensive agent

Relatively potent and specific in vitro and in vivo (oral or intravenous) inhibition of angiotensin-converting enzyme by a nonpeptidic compound, captopril (SQ 14,225; d-3-mercapto-2-methylpropanoyl-l-poline), was demonstrated in excised guinea pig ileum and in rats, rabbits, cats, dogs, and monkeys. The design of captopril was based on a hypothetical model of the active site of the enzyme. Captopril, in vitro or in vivo, was about ten times as potent as teprotide. Inhibition of angiotensin-converting enzyme was evaluated in vitro and in vivo by inhibition of the contractile or vasopressor activity of angiotensin I or by augmentation of the contractile or vasodepressor activity of bradykinin. Acute of subacute dosage with captopril moderately to markedly lowered the blood pressure of the renin-dependent aorticligated and the conscious two-kidney Goldblatt hypertensive rat; in the latter, the effect was intensified by concomitant dosage with a thiazide diuretic. Furthermore, the life-prolonging effects of captopril in renal hypertensive rats were augmented by a thiazide diuretic. In the two-kidney Goldblatt rat, acute captopril (p.o.) was about ten times as potent as teprotide (s.c.) in lowering blood pressure. Acute or subacute oral doses of captopril moderately reduced the blood pressure of the spontaneously hypertensive Wistar-Kyoto rat; chronic dosage almost normalized blood pressure. Captopril produced little or no hypotension in the saltreplete normotensive Wistar-Kyoto rat. Bilateral nephrectomy virtually abolished the hypotensive activity of captopril in the spontaneous hypertensive rat. The results suggest that captopril acts in large part by inhibiting the renin-angiotensin-aldosterone system to reduce elevated blood pressure, especially in renindependent models of hypertension; the roles of the kallikrein-kinin-prostaglandin systems and sodium balance remain to be elucidated. Captopril also lowers blood pressure in apparently non-renin-dependent types of hypertension by mechanisms that are as yet undefined.     

Influence of Alloying Element Mg on Na and Sr Modifying Al-7Si Hypoeutectic Alloy

The influence of alloying element Mg on Na and Sr modifying Al-7Si hypoeutectic alloys was investigated. The residual content of Na and the morphology of modified eutectic silicon were characterized. It was found that the alloying element Mg had an enhanced effect on the uptake of sodium in the Al-7Si hypoeutectic alloy modified by the Na-contained modifier. Moreover, the morphology of eutectic silicon of the modified Al-7Si alloys was significantly different from that of Al-7Si-0.4Mg alloys in the present research. When the addition of the modifier is enough, both modifiers could entirely modify the eutectic silicon phase of Al-7Si alloys, while incompletely modified eutectic silicon was observed in both Na-modified and Sr-modified Al-7Si-0.4Mg alloy. It was observed that there was an adhering relationship between the partially modified eutectic silicon with Mg-rich phases. According to the results, it can be proposed that the addition of Mg will affect the solidification behavior of alloys, thereby, leading to the incomplete modification of eutectic silicon phases.     

89锶内照射治疗不同原发癌转移性骨痛的疗效观察

目的研究^89锶（^89Srel2）内照射治疗转移性骨痛的疗效及其与不同原发癌的关系。方法对^99m/Tc—MDP全身骨显像证实不同原发肿瘤多发性骨转移骨痛患者93例。使用^89Srcl2治疗后．观察治疗前后疼痛缓解程度及骨转移灶改善情况,评价其对不同原发肿瘤骨转移灶及转移性骨痛的治疗价值。结果93例中70例疼痛出现不同程度的缓解,总缓解率为75.3％。其中完全缓解（疼痛基本消失）10例,占10．8％;部分缓解（疼痛明显减轻,能正常活动）41例,占44．1％;轻度缓解（疼痛有所减轻,但仍不能正常活动）19例．占20．4％。无效（疼痛加重）23例。占24．7％。结论^89Srel2是一种安全、有效的转移性骨痛的治疗制剂。其对骨转移病灶也有治疗效应。止痛效果以前列腺癌和乳腺癌骨转移所致骨痛的疗效较显著。